Rescheduling vs. Descheduling: What It Means for Cannabis

By Alex Hearding, Founder & President – Red Wolf Risk LLC

The Headlines Miss the Point

News outlets have been celebrating the proposal to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. At first glance, this looks like long-awaited progress, but for those of us who live and work in the cannabis industry, it’s far from the finish line.

Rescheduling is not legalization. It’s not even real reform. And it leaves most of the systemic barriers in place.

To understand why, we have to look at what rescheduling actually does, and what only descheduling can.

Rescheduling: Reclassifying Cannabis as a Controlled Substance

Under Schedule III, cannabis would still be considered a controlled substance, alongside anabolic steroids and certain prescription drugs. That means:

So, while rescheduling might make it easier for researchers and doctors to study cannabis, it doesn’t fix the fundamental contradictions of the state–federal divide.

As dnot3.org notes, this is a “regulatory reshuffle, not a liberation.” It preserves prohibition under a new label.

Descheduling: Removing Cannabis from the Controlled Substances Act

Descheduling, on the other hand, means removing cannabis entirely from the Controlled Substances Act (CSA).

That would allow Congress, states, and regulatory agencies like the FDA and USDA to build a rational, risk-based framework, treating cannabis like alcohol, tobacco, or other botanical commodities, depending on use case.

Descheduling would enable:

In short, descheduling would finally allow the cannabis industry to operate as a legitimate, regulated sector of the U.S. economy.

Why This Distinction Matters for Operators

For cannabis operators, this distinction isn’t theoretical, it’s existential.

Rescheduling might relieve some tax pressure (by easing IRS 280E restrictions), but it won’t:

Descheduling, however, would open the door to the same regulatory maturity that Red Wolf Risk prepares clients for — one built around quality systems, data integrity, and risk management consistent with FDA and ISO standards.

That’s why building compliance, documentation, and GMP/QMS frameworks now is the smartest way to future-proof your business for the post-prohibition era.

The Path Forward

As dnot3.org explains, rescheduling under Schedule III is an administrative shortcut that avoids confronting the outdated logic of prohibition. It’s a half-measure that offers optics but not structure, and it risks consolidating control in the hands of a few pharmaceutical companies rather than empowering the existing regulated market.

If policymakers truly want to modernize cannabis regulation, descheduling is the only honest path, one that recognizes the plant’s safety profile, economic contribution, and cultural legitimacy.

Conclusion

Rescheduling may be a step toward progress, but descheduling is the step toward freedom.

The cannabis industry doesn’t need another controlled-substance category, it needs a rational, science-based system that rewards safety, transparency, and quality. Until cannabis is descheduled, operators will continue to navigate a patchwork of rules that punish compliance and stifle innovation.

At Red Wolf Risk, we’re helping businesses prepare for that future, one built on operational excellence, validated systems, and measurable quality, so when the wall finally falls, they’re already ready to lead.

Alex Hearding is the Founder and President of Red Wolf Risk and has more than 17 years of experience in cannabis operations, risk management, quality systems, and regulatory compliance.